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A B S T R A C T
This is a protocol for a Cochrane Review (Overview). The objectives are as follows:
Main objectives
• To summarise Cochrane Reviews on the efficacy and safety of interventions for escalation of treatment for children with acute
exacerbations of asthma
Secondary objectives
• To identify gaps in the current evidence base that will inform recommendations for future research and subsequent Cochrane
Reviews
• To categorise information on reported outcome measures used in trials of escalation of treatment for acute exacerbations of
asthma in children, and to make recommendations for development and reporting of standard outcomes in future trials and reviews
• To identify relevant research papers that have been published since the date of publication of each included review
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B A C K G R O U N D
Description of the condition
Asthma is defined as “a chronic inflammatory disorder associated
with variable airflow obstruction and bronchial hyper-responsive-
ness” (Papadopoulos 2012). Clinical features include recurrent
episodes of cough, shortness of breath, wheeze, or chest tightness
(Papadopoulos 2012), which may be triggered by viral respiratory
infection, exercise, a change in the weather, or exposure to aller-
gens or irritants (GINA 2017).
Airflow obstruction results primarily from episodic bronchocon-
striction due to contraction of airway smooth muscle. However,
other mechanisms also contribute, including mucosal oedema, in-
flammation, mucus hyper-secretion, airway hyper-responsiveness,
and airway remodelling (NHLBI 2007).
The diagnosis and management of asthma are complicated in
younger children, particularly those from birth to five years (Cave
2014). In this age group, viral-induced wheezing is very common
and has clinical features overlapping those of asthma but does
not necessarily have the same longer-term implications (Martinez
1995; Caudri 2009; Konstantinou 2013).
Care of a childwith asthma requires long-termmanagement aimed
at preventing recurrent exacerbations, as well as acutemanagement
of symptomatic exacerbations. Treatment for asthma addresses the
underlying pathophysiological mechanisms of inflammation and
bronchoconstriction.
An asthma exacerbation is defined as an “acute or subacute episode
of progressively worsening shortness of breath, cough, wheezing,
and chest tightness - or some combination of these symptoms”
(NHLBI 2007). First-line therapy for management of acute exac-
erbations of asthma is well established and requires titrated oxygen
delivery and administration of intermittent inhaled short-acting
beta2-agonists (SABAs) and oral corticosteroids (OCSs) (NHLBI
2007; National Asthma Council Australia 2016; GINA 2017).
Description of the interventions
Most children with asthma have mild or moderate exacerbations
and respond well to first-line therapy (Powell 2003; Kelly 2004;
Giordano 2012; O’Connor 2014). A minority of children with
severe exacerbations are unresponsive to first-line therapy and re-
quire escalation of treatment (O’Connor 2014; Biagini Myers
2015; Morris 2015). Many options are available for escalation of
treatment, but the choice of regimens shows considerable variabil-
ity amongst clinicians (Babl 2008; Lyttle 2015).
Escalation of treatment can be grouped into the following broad
categories.
• Additional inhaled bronchodilators, including continuous
inhaled β2-agonists, anticholinergic medications such as
ipratropium, and nebulised magnesium sulfate.
• Parenteral bronchodilators, including selective β2-agonists
such as salbutamol or terbutaline; adrenaline (epinephrine), an
agonist at both α- and β-receptors; magnesium sulfate;
methylxanthines such as theophylline or aminophylline; and
ketamine. Subcutaneous, intramuscular, and intravenous routes
may be utilised, and intravenous treatment may be delivered as a
single loading dose or as a continuous infusion.
• Interventions to reduce the work of breathing, including
inhalation of heliox (a mixture of helium and oxygen),
administration of high-flow humidified nasal oxygen therapy, or
provision of non-invasive ventilation with the use of continuous
positive airway pressure (CPAP) or bi-level positive airway
pressure (BiPAP).
How the intervention might work
Bronchodilators
Relief of bronchoconstriction, a major therapeutic target in an
acute exacerbation of asthma, is achieved by several pharmacologi-
cal agents acting by various mechanisms. Inhaled short-acting β2-
agonists (SABAs), such as salbutamol and terbutaline, are effec-
tive, provide a rapid onset of action, and are accepted as first-line
therapy for acute asthma exacerbations (Vezina 2014). In young
children, administration using a spacer or holding chamber is pre-
ferred over delivery via nebuliser (Ferguson 2006). In patients with
severe exacerbations unresponsive to first-line administration of
intermittent inhaled SABA, cliniciansmaywish to administer con-
tinuous inhaled SABA to saturate all available respiratory tract β2-
receptors and achieve maximum bronchodilation from this path-
way (Kenyon 2014).
Inhaled anticholinergic agents such as ipratropium bromide are
thought to cause bronchodilation by relieving cholinergic bron-
choconstriction and reducing mucosal oedema and airway secre-
tions (Vezina 2014). Although not as effective as β2-agonists, it
has been suggested that combining both medications may lead to
greater bronchodilation than use of either agent alone (Griffiths
2013).
Magnesium sulfate has been demonstrated to be an effective bron-
chodilator and may be administered by nebuliser or by the in-
travenous route. Its mode of action is thought to relate to direct
smooth muscle relaxation; however, additional mechanisms may
relate to blocking calcium ion influx into smooth muscle cells,
modulating mast cell histamine release, anti-inflammatory prop-
erties, and cholinergic neural transmission (Powell 2012). Some
evidence suggests that simultaneous administration of magnesium
sulfate and a β2-agonist has an additive bronchodilator effect, per-
haps owing to magnesium sulfate augmenting the β-receptor ag-
onist response (Neame 2015).
In the setting of severe acute asthma, it has been suggested that
inhaled β2-agonists may not reach their site of action through the
2Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
airway owing to significant airflow obstruction, and that systemic
(subcutaneous or intravenous) administration of bronchodilators
may lead to a more rapid therapeutic response (Travers 2012).
Adrenaline (epinephrine) is a potent β-agonist with bronchodi-
lating effects similar to the more selective β2-agonists. Histori-
cally, parenteral adrenaline was a standard therapy for acute asthma
(Rees 1967; Shim 1984); however, similar clinical efficacy and
the less invasive nature of inhaled bronchodilators as reported by
Naspitz 1987 have led clinicians to reserve this treatment as an op-
tion for severely ill patients unresponsive to inhaled therapy (Hon
2017).
Methylxanthines such as theophylline and aminophylline have
been used for many years to treat patients with asthma. Bron-
chodilator effects may be due to inhibition of phosphodiesterase,
leading to accumulation of cyclic adenosine monophosphate
(cAMP) in smoothmuscle cells, adenosine antagonism, and release
of catecholamines (Neame 2015). Other actions are thought to in-
clude anti-inflammatory and immunomodulatory effects (Neame
2015).
Ketamine is commonly used in the emergency department (ED)
for procedural sedation, analgesia, and intubation, and has many
effects, including dissociative anaesthesia, analgesia, amnesia, and
anxiolysis. It can also induce bronchodilation, possibly as a sym-
pathomimetic effect or a direct effect on bronchial smooth muscle
(Jat 2012). Other potential effects include immunomodulation
and inhibition of vagal outflow (Goyal 2013).
Interventions to reduce the work of breathing
Room air comprises nitrogen (79%) and oxygen (21%). Heliox
(helium-oxygen mixture) is produced when helium replaces nitro-
gen, leading to a less dense gas mixture. Theoretically, this may
reduce turbulent airflow and airflow obstruction in patients with
asthma. Heliox has also been used to deliver nebulised therapy, as
it has been suggested that it may lead to improved transport of
medication to the distal airways (Rehder 2017).
Non-invasive respiratory support can be delivered with the use
of high-flow nasal cannulae (HFNC), continuous positive airway
pressure (CPAP), or bi-level positive airway pressure (BiPAP). Pa-
tients with severe asthma often develop elevated intrinsic positive
end-expiratory pressure (PEEP). It is theorised that delivery of ex-
trinsic positive pressure via face mask or nasal cannulae may over-
come this intrinsic pressure, thereby reducing the work of breath-
ing.
High-flow nasal cannulae provide warmed, humidified gas deliv-
ered via nasal prongs at a flow rate that exceeds the patient’s peak in-
spiratory flow rate. This results in washout of anatomic dead space
and also provides some PEEP, although the PEEP delivered is less
consistent than that provided by CPAP or BiPAP (Rehder 2017).
High-flow delivery is more comfortable and therefore is better tol-
erated with less requirement for sedation than other methods of
non-invasive respiratory support (Baudin 2017).
CPAP provides constant pressure throughout the respiratory cy-
cle, and BiPAP provides variable pressure according to phases of
the respiratory cycle, with higher pressure delivered during inspi-
ration. Positive effects of CPAP and BiPAP include a direct bron-
chodilating effect, improved alveolar recruitment, improved air-
flow, re-expansion of areas of collapse, reduced hyperinflation, and
reduced work of breathing (Korang 2016).
Why it is important to do this overview
Clinical rationale
Asthma is a common reason for paediatric visits to the ED (Alpern
2006; Acworth 2009); it is one of the most common reasons for a
child to be admitted to hospital after an ED visit (Weiss 2011). In
the USA, the rate of paediatric ED visits for asthma increased by
13.3% between 2001 and 2010 (Nath 2015), and in the UK, it
is estimated that a child is admitted to hospital every 20 minutes
owing to an asthma attack (Asthma UK).
The care of children with asthma is based upon escalation of treat-
ment in response to disease severity: Mild disease receives less in-
tensive treatment than severe disease. Broadly speaking, interven-
tions take the form of inhaled bronchodilators, parenteral (intra-
venous or subcutaneous) pharmacotherapy, and mechanical ef-
forts to reduce the work of breathing. With increasing ’level of
treatment’ come risks of increasing costs, patient discomfort, po-
tential for complications, and requirement for monitoring and/
or transfer to intensive care units. Some treatments - particularly
intravenous bronchodilators or assisted ventilation - are given in
higher-acuity settings such as intensive care, and other treatments
may be given in a standard ward environment.
Variation in the management of acute severe asthma in children
is considerable and may be due to considerations around efficacy
and safety, cost, clinical experience, and individual practitioner
preference. A recent survey of emergency physicians in the UK
and Ireland found that over half preferred salbutamol as first-line
intravenous treatment, while 28% preferred magnesium sulfate
and 15% preferred aminophylline (Lyttle 2015). An earlier survey
of paediatric emergency specialists in Australia and New Zealand
found that aminophylline was used by 45%, intravenous mag-
nesium sulfate by 55%, and intravenous salbutamol by 87% of
respondents (Babl 2008). A recent prospective study of 24 EDs
in the UK and Ireland found wide variation in the prevalence of
intravenous treatment for acute paediatric asthma, ranging from
0% to 19.4% (Morris 2015).
With a large number of treatment options and wide variation in
self-reported and actual practice, it is important to have a single
comprehensive and user-friendly document that provides the best
available evidence upon which to base clinical decisions. There is
a need to present available evidence clearly to assist clinicians and
other users. The purpose of a Cochrane overview is to systemati-
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cally summarise evidence from a range of Cochrane intervention
reviews for a single health condition (Becker 2011). The overview
will document current evidence for the efficacy of various avail-
able interventions and will provide information about toxicity and
adverse effects.
Potential additional benefits of this overview will include a clear
foundation upon which further research can be based and an un-
derstanding of reported outcome measures, which may be used to
assist in development of a set of core outcome measures for future
clinical trials.
Methodological rationale
Currently, the Cochrane Airways Group has prepared approxi-
mately 50 published reviews on the effectiveness of various in-
terventions for acute asthma. This includes 43 reviews on phar-
macotherapy and another seven reviews on non-pharmacotherapy
interventions. Given the large number of potentially relevant re-
views and the likely heterogeneity in eligibility criteria and study
outcomes, we have chosen to utilise an overview design rather than
a network meta-analysis as the first step in assessing the literature.
O B J E C T I V E S
Main objectives
• To summarise Cochrane Reviews on the efficacy and safety
of interventions for escalation of treatment for children with
acute exacerbations of asthma
Secondary objectives
• To identify gaps in the current evidence base that will
inform recommendations for future research and subsequent
Cochrane Reviews
• To categorise information on reported outcome measures
used in trials of escalation of treatment for acute exacerbations of
asthma in children, and to make recommendations for
development and reporting of standard outcomes in future trials
and reviews
• To identify relevant research papers that have been
published since the date of publication of each included review
M E T H O D S
Criteria for considering reviews for inclusion
Types of reviews
Wewill include reviews on treatment of patients with acute asthma
published in theCochrane Database of Systematic Reviews (CDSR).
We will include Cochrane Reviews of randomised controlled trials
(RCTs) and quasi-randomised controlled clinical trials (CCTs).
Types of participants
We will include reviews of children with a physician-diagnosed
acute exacerbation of asthma. We will define a child as any person
aged younger than 18 years. However, as the definition of ’child’
may vary between reviews, we intend to include any studies in
which a population is described as children, and we will record the
ages included within each review.We will include reviews of adults
and children in which the results for children can be separated
from the results for adults.
Types of interventions/comparisons
We will include all treatments that may be considered escalation
of therapy for acute exacerbations of asthma. We will not include
reviews examining interventions including only corticosteroids or
intermittent inhaled β2-agonists.
We will divide treatments into the following categories, consistent
with steps in the escalation of therapy (inhaled treatment, par-
enteral treatment, and other interventions to reduce the work of
breathing).
• Inhaled bronchodilators.
• ◦ Continuous inhaled β2-agonists (via spacer or
nebuliser).
• ◦ Anticholinergic medications.
◦ Magnesium sulfate.
• Parenteral bronchodilators.
◦ β2-agonists.
◦ Adrenaline/epinephrine.
◦ Magnesium sulfate.
◦ Methylxanthines.
◦ Ketamine.
• Interventions to reduce the work of breathing.
◦ Heliox.
◦ High-flow nasal cannulae.
◦ Non-invasive ventilation (CPAP or BiPAP).
Types of comparisons
We will include reviews with all possible comparisons, that is,
versus placebo and/or versus another active comparator (ongoing
first-line treatment or an alternative intervention).
Types of outcome measures
Primary outcomes
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• Length of stay (duration of ED stay and duration of
inpatient stay)
• ED disposition (hospital admission/intensive care unit
(ICU) admission/ED discharge)
• Number of adverse events in each treatment group
Secondary outcomes
• Symptom scores/clinical asthma scores (such as the
Pulmonary Index (Becker 1984), the Clinical Asthma Score
(Parkin 1996), the Pediatric Respiratory Assessment Measure
(Ducharme 2008), and any other scores identified in the
included reviews)
• Lung function (peak expiratory flow rate (PEFR), forced
expiratory volume in one second (FEV1), and other measures
identified in included reviews)
• Adverse events (vomiting, nausea, tremor, tachycardia,
convulsions, and any other adverse events identified in included
reviews)
• Vital signs (pulse, blood pressure, respiratory rate, and pulse
oximetry)
• Requirement for additional bronchodilator treatment
• Requirement for respiratory support (intubation, non-
invasive ventilation)
• Economic outcomes such as healthcare costs
We will report on the primary and secondary outcomes outlined
above. However, we will tabulate all outcomes identified in the
overview to present a taxonomy of outcomes for future reviews on
this topic.
Search methods for identification of reviews
We will search for systematic reviews in the Cochrane Library us-
ing the filter for reviews. We will identify Cochrane Review pro-
tocols and titles for future inclusion. We will use the search terms
“asthma” and “respiratory sounds” (which includes the medical
subject heading (MeSH) term for “wheeze”). Our search strategy
is detailed in Appendix 1.
We will include only the most recently published version of each
review. We will not include protocols and earlier versions of a re-
view that have been superseded. We do not intend to include sys-
tematic reviews from outside the Cochrane Library. If multiple re-
views address the same question, we will examine them for unique
content, and if none is found, we will include the most up-to-date
review. If multiple reviews address the same question and unique
content is found in each, we will include them and will extract the
unique data.
To identify relevant research papers that have been published since
the data of publication for each included review, we intend to
utilise the search strategy of each included review. We will sup-
plement this by cross-checking against current British Thoracic
Soceity/Scottish Intercollegiate Guidelines Network (BTS/SIGN)
and Global Initiative for Asthma (GINA) guidelines.
Data collection and analysis
Selection of reviews
We will assess in two stages the eligibility of identified Cochrane
Reviews. Two independent review authors will screen each title
and abstract. A third review author will resolve discrepancies when
the two review authors cannot reach consensus. Two independent
review authors will assess in full text all titles/abstracts that were
selected by consensus. Again, we will attempt to resolve discrep-
ancies in consensus between the two review authors by including
a third review author if required.
We will attach a table of excluded reviews as an appendix.
Data extraction and management
Two review authors will independently extract data using an elec-
tronic data extraction form specifically designed for this project.
We will involve a third review author to resolve disagreements.
Data to be extracted (see Appendix 2) include the following.
• Details of the review, including first author name, year of
publication, number of included primary studies (countries and
years in which the original studies were conducted), eligibility
criteria of included reviews, numbers of included participants,
and sample size of included RCTs. We will map systematic
reviews to their included RCTs.
• Details of trial populations, including age and severity of
asthma (including inclusion criteria and definition of
exacerbation of asthma for each review, treatment before
enrolment, and severity of asthma at enrolment).
• Settings (ED, hospital ward, ICU).
• Types of interventions.
• Dose, duration, and frequency of intervention
administration.
• Description of the comparison (placebo, regular doses of
bronchodilators).
• Description of outcome measures used, including our
predefined primary and secondary outcomes and all other
outcomes reported.
• Timing of determination of outcome measures and
duration of follow-up.
• Risk of bias assessments of RCTs included in the reviews.
• For each predetermined primary and secondary outcome
measure, and for all additional outcomes, numbers of
participants in intervention and control groups; control event
rate; effect estimates for the pooled risk ratio; odds ratio, hazard
ratio, standardised mean difference, or absolute risk reduction
and corresponding 95% confidence intervals (if not provided, we
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will calculate these, using the equations published in the
Cochrane Handbook for Systematic Reviews of Interventions
(Schüneman 2017)); details of statistical tests for heterogeneity,
including the Chi2 test and the I2 test.
• Conclusions of each review.
• Review recommendations for further research.
• Quality assessment tools used (e.g. GRADE), along with
the mean or median and the range of any reported quality scores.
If the included systematic review includes all studies relevant to
a particular outcome, we will extract summary data alone. We
will extract only data from studies conducted exclusively among
children or for which authors of the systematic review have been
able to enter data from children.
If we identify overlapping information across systematic reviews at
the data extraction stage, we will extract data only from the most
recently published review. We will acknowledge overlap among
different reviews (overlapping trials), depict any potential overlap
in tables, and discuss this limitation in the results.
If we identify discrepant data across systematic reviews, we will ex-
tract data from all included reviews and will reconcile the discrep-
ancies by contacting the authors of included reviews, retrieving
primary studies from the included reviews, and searching relevant
trial registries. We will discuss potential discrepancies in data in
the Results section.
We will present the data in a series of summary tables.
Assessment of methodological quality of included
reviews
Two review authors will independently assess the risk of bias of
included reviews using the Risk of Bias in Systematic Reviews
(ROBIS) tool (Whiting 2016). The ROBIS tool (see Appendix 3)
consists of three phases: assessment of relevance of the systematic
review to the study question, identification of potential concerns
regarding the review process, and a judgement of risk of bias. We
will report in a table assessment for individual ROBIS items or
domains (along with the rationale for judgements for each assess-
ment).
We define a high-quality meta-analysis as one that has a low risk
of bias judgements for the first three domains of the ROBIS tool,
namely, specification of study eligibility (domain 1), methods used
to identify and/or select studies (domain 2), and methods used to
collect data and appraise studies (domain 3) (Whiting 2016). We
will choose the meta-analysis that we judged as having low risk of
bias in all four ROBIS domains, as well as the meta-analysis that
most closely matches our overview PICO criteria if we find more
than one high-quality meta-analysis.
We will use the risk of bias assessment to conduct sensitivity anal-
yses, but we will not exclude reviews on the basis of the risk of bias
assessment.
We will present a summary of this information according to guide-
lines provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2017).
Quality of evidence in included reviews
Two overview authors will independently evaluate the certainty of
evidence on the basis of judgements made by the authors of the
original Cochrane Reviews, if provided.
We will assess the certainty of evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach (Balshem 2011).
First, we will extract the GRADE assessments for each systematic
review for each independent outcome. We will first assess whether
the domain judgements are consistent; if they are inconsistent, we
will try to reconcile the inconsistency by comparing extracted data
between the reviews for missing or discrepant data, contacting the
authors of the primary studies, or searching trial registries, if two or
more systematic reviews report GRADE assessments for the same
outcome. We will choose the highest-quality meta-analysis from
which to extract effect estimates for our GRADE assessment of
inconsistency and imprecision if we continue to note inconsistency
in the reported GRADE domains (or none reported).
We will independently conduct this assessment by construct-
ing ’Summary of findings’ tables using GRADEpro software
(GradePro 2015)if the original review published no GRADE as-
sessment, of if outcome data in our overview have been re-analysed
from a subset of primary studies within a review.
We will base our assessment of the certainty of evidence in in-
cluded reviews on data provided in the ‘Characteristics of included
studies’, ‘Risk of bias’, and ‘Summary of findings’ tables provided
in the included reviews, and we will present a summary of this in-
formation according to guidelines provided in theCochraneHand-
book for Systematic Reviews of Interventions (Higgins 2017).
We will summarise the evidence for our primary outcomes in a
’Summary of findings’ table.
Dealing with missing data
We will address data missing from an included systematic review
or variation in information reported across reviews by retrieving
and examining the full reports of RCTs included in the system-
atic reviews; contacting systematic review authors for missing in-
formation or clarification; searching systematic review protocols;
and/or searching registries of systematic reviews or clinical trials
for further information. This overview will include discussion on
potential discrepancies with information provided in the original
reviews.
Data synthesis
We will tabulate PICO (population, intervention, control, and
outcome) elements at the review level. Results tables will include
effect estimates, 95% confidence intervals (CIs), and measures of
heterogeneity/risk of bias, as appropriate.
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We aim to group data into the three broad groups described above:
inhaled bronchodilators, parenteral bronchodilators, and inter-
ventions to reduce the work of breathing. We intend to compare
all outcomes between inhaled bronchodilators (e.g. standard ther-
apy/placebo vs continuous nebulised SABA vs inhaled magne-
sium), between parenteral bronchodilators (e.g. standard therapy/
placebo vs aminophylline vs magnesium vs ketamine vs salbuta-
mol vs terbutaline), and between interventions to reduce the work
of breathing (standard therapy/placebo vs CPAP vs BiPap vs he-
liox vs HFNC). We will extract effect estimates from the included
systematic reviews, categorised by intervention and primary and
secondary outcomes, and will present them in tables and figures.
We will structure narrative descriptions of effect estimates of the
included reviews according to systematic review risk of bias and
GRADE assessment.
We will also assess the impact of inclusion criteria (severity of
asthma), treatment before enrolment (including type of first-line
intervention applied), and control treatment on the effects of in-
terventions.
The choice of effect estimate for summary and tabulation will de-
pend on the outcomes reported in various reviews. We intend to
standardise the outcomes reported if an outcome is expressed dif-
ferently between reviews. We will standardise to risk ratios (RRs)
or odds ratios (ORs) for dichotomous outcomes.Wewill standard-
ise to mean differences (MDs) or standardised mean differences
(SMDs) by using equations published in the Cochrane Handbook
for Systematic Reviews of Interventions for continuous outcomes
(Higgins 2011a).
The exact method chosen for graphical display will depend on the
number of studies available for each particular outcome. We will
use Review Manager 5 (Cochrane 2014) to generate forest plots
of standardised effect measures and will use these to graphically
present the results, with each review representing one line in the
forest plot. Other options include using harvest plots as described
in Crick 2015 or bar graphs.
We will discuss the limitations of currently available evidence with
regards to heterogeneity of inclusion criteria for each review, con-
sistency of effect size for each intervention, and consistent use of
outcome measures. We will identify gaps in the current evidence
base and will make recommendations for future research.
Assessment of non-statistical heterogeneity
We will determine whether there is clinical heterogeneity between
reviews (i.e. differences in severity of asthma or differences in treat-
ment administered before enrolment) by assessing the inclusion
criteria of each systematic review. We will also assess clinical het-
erogeneity within each systematic review that will contribute to
the quality assessment of each review.
We will examine the heterogeneity of evidence for each primary
outcome by summarising the range of I2 variation. Heterogeneity
is considered not important if the I2 variation is 0 to 40%, mod-
erate if 30% to 60%, substantial if 50% to 90%, and considerable
if 75% to 100% (Deeks 2017).
We will identify commonly used outcomes and will categorise
them in a taxonomy by creating a list of all outcomes and dis-
cussing their categorisation among the review author group until
consensus is reached. This taxonomy will inform recommenda-
tions for a core set of outcome measures, which may be applicable
in future RCTs.
Subgroup analysis
Given the pathophysiological differences between preschoolers
and older children, we intend to subgroup studies of children from
birth to five years of age and children aged six to 18 years (or
younger and older children as defined by review authors) and to
provide separate summary tables within the overview.
Finally, we will group studies occurring in the ED/outpatient set-
ting separately from those occurring in the inpatient setting (ward
or intensive care unit).
We will extract summary event data for each treatment/placebo
group from the included reviews for all subgroup analyses.
Sensitivity analysis
We will conduct sensitivity analysis based on the ROBIS assess-
ment of systematic reviews by comparing results of all reviews
against data derived only from reviews in which the ROBIS tool
identified no domains with a “high” level of concern (i.e. by ex-
cluding studies that have one or more domains in the ROBIS tool
rated as causing a “high” level of concern).
A C K N OW L E D G E M E N T S
We thank Liz Stovold, Information Specialist, Cochrane Airways
Group, for advice on search strategies for this overview.
Katherine Pike was the Editor for this review and commented
critically on the review.
This project was supported by the National Institute for Health
Research (NIHR), via Cochrane Infrastructure funding to the
Cochrane Airways Group. The views and opinions expressed
therein are those of the review authors and do not necessarily re-
flect those of the Systematic Reviews Programme, NIHR, NHS,
or the Department of Health.
7Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Acworth 2009
Acworth J, Babl F, Borland M, Ngo P, Krieser D, Schutz
J, et al. Patterns of presentation to the Australian and
New Zealand Paediatric Emergency Research Network.
Emergency Medicine Australasia 2009;21(1):59–66.
Alpern 2006
Alpern ER, Stanley RM, Gorelick MH, Donaldson A,
Knight S, Teach SJ, et al. Epidemiology of a pediatric
emergency medicine research network: the PECARN
core data project. Pediatric Emergency Care 2006;22(10):
689–99.
Asthma UK
Asthma UK. Asthma facts and statistics.
www.asthma.org.uk/about/media/facts-and-statistics/
(accessed 3 August 2017).
Babl 2008
Babl FE, Sheriff N, Borland M, Acworth J, Neutze J, Krieser
D, et al. Paediatric acute asthma management in Australia
and New Zealand: practice patterns in the context of
clinical practice guidelines. Archives of Disease in Childhood
2008;93(4):307–12.
Balshem 2011
Balshem H, Helfand M, Schunemann HJ, Oxman AD,
Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the
quality of evidence. Journal of Clinical Epidemiology 2011;
64(4):401–6.
Baudin 2017
Baudin F, Buisson A, Vanel B, Massenavette B, Pouyau R,
Javouhey E. Nasal high flow in management of children
with status asthmaticus: a retrospective observational study.
Annals of Intensive Care 2017;7(1):55.
Becker 1984
Becker AB, Nelson NA, Simons FE. The pulmonary index.
Assessment of a clinical score for asthma. American Journal
of Diseases of Children 1984;138(6):574–6.
Becker 2011
Becker LA, Oxman AD. Chapter 22: Overviews of reviews.
In: Higgins JP, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Biagini Myers 2015
Biagini Myers JM, Simmons JM, Kercsmar CM, Martin LJ,
Pilipenko VV, Austin SR, et al. Heterogeneity in asthma
care in a statewide collaborative: the Ohio Pediatric Asthma
Repository. Pediatrics 2015;135(2):271–9.
Caudri 2009
Caudri D, Wijga A, Schipper CM, Hoekstra M, Postma
DS, Koppelman GH, et al. Predicting the long-term
prognosis of children with symptoms suggestive of asthma
at preschool age. Journal of Allergy and Clinical Immunology
2009;124(5):903–10.e1-7.
Cave 2014
Cave AJ, Atkinson LL. Asthma in preschool children: a
review of the diagnostic challenges. Journal of the American
Board of Family Medicine 2014;27(4):538–48.
Cochrane 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Crick 2015
Crick K, Wingert A, Williams K, Fernandes RM, Thomson
D, Hartling L. An evaluation of harvest plots to display
results of meta-analyses in overviews of reviews: a cross-
sectional study. BMC Medical Research Methodology 2015;
15:91.
Deeks 2017
Deeks JJ, Higgins JPT, Altman DG (editors), on behalf
of the Cochrane Statistical Methods Group. Chapter
9: Analysing data and undertaking meta-analyses. In:
Higgins JPT, Churchill R, Chandler J, Cumpston MS
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.2.0 (updated June 2017).
The Cochrane Collaboration, 2017. Available from
www.training.cochrane.org/handbook.
Ducharme 2008
Ducharme FM, Chalut D, Plotnick L, Savdie C, Kudirka
D, Zhang X, et al. The pediatric respiratory assessment
measure: a valid clinical score for assessing acute asthma
severity from toddlers to teenagers. Journal of Pediatrics
2008;152(4):476-80, 480.e1.
Ferguson 2006
Ferguson C, Gidwani S. Best evidence topic reports.
Delivery of bronchodilators in acute asthma in children.
Emergency Medicine Journal 2006;23(6):471–2.
GINA 2017
GINA 2017. Global Initiative for Asthma. Global Strategy
for Asthma Management and Prevention, 2017. Available
from www.ginaasthma.org (accessed 3 August 2017).
Giordano 2012
Giordano K, Rodriguez E, Green N, Armani M, Richards J,
Shaffer TH, et al. Pulmonary function tests in emergency
department pediatric patients with acute wheezing/asthma
exacerbation. Pulmonary Medicine 2012;2012:724139.
[DOI: 10.1155/2012/724139
Goyal 2013
Goyal S, Agrawal A. Ketamine in status asthmaticus: a
review. Indian Journal of Critical Care Medicine 2013;17(3):
154–61.
GradePro 2015 [Computer program]
McMaster University, 2015 (developed by Evidence Prime,
Inc.). Available from gradepro.org.. GRADEpro GDT:
GRADEpro Guideline Development Tool. McMaster
University, 2015 (developed by Evidence Prime, Inc.).
Available from gradepro.org., 2015.
8Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Griffiths 2013
Griffiths B, Ducharme FM. Combined inhaled
anticholinergics and short-acting beta2-agonists for initial
treatment of acute asthma in children. Cochrane Database
of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/
14651858.CD000060.pub2
Higgins 2011a
Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting
studies and collecting data.. In: Higgins JPT, Green S
(editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.handbook.cochrane.org.
Higgins 2017
Higgins JPT, Altman DG, Sterne JAC, on behalf of the
Cochrane Statistical Methods Group and the Cochrane
Bias Methods Group. Chapter 8: Assessing risk of bias in
included studies. In: Higgins JPT, Churchill R, Chandler
J, Cumpston MS (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.2.0 (updated
June 2017). The Cochrane Collaboration, 2017. Available
from www.training.cochrane.org/handbook.
Hon 2017
Hon KL, Leung AK. Management of status asthmaticus in
children. Recent Patents on Inflammation and Allergy Drug
Discovery 2017;11(1):12–21.
Jat 2012
Jat KR, Chawla D. Ketamine for management of acute
exacerbations of asthma in children. Cochrane Database
of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/
14651858.CD009293.pub2
Kelly 2004
Kelly AM, Kerr D, Powell C. Is severity assessment after
one hour of treatment better for predicting the need for
admission in acute asthma?. Respiratory Medicine 2004;98
(8):777–81.
Kenyon 2014
Kenyon CC, Fieldston ES, Luan X, Keren R, Zorc JJ. Safety
and effectiveness of continuous aerosolized albuterol in the
non-intensive care setting. Pediatrics 2014;134(4):e976–82.
Konstantinou 2013
Konstantinou GN, Xepapadaki P, Manousakis E, Makrinioti
H, Kouloufakou-Gratsia K, Saxoni-Papageorgiou P, et al.
Assessment of airflow limitation, airway inflammation,
and symptoms during virus-induced wheezing episodes in
4- to 6-year-old children. Journal of Allergy and Clinical
Immunology 2013;131(1):87–93.e1-5.
Korang 2016
Korang SK, Feinberg J, Wetterslev J, Jakobsen JC. Non-
invasive positive pressure ventilation for acute asthma in
children. Cochrane Database of Systematic Reviews 2016,
Issue 9. [DOI: 10.1002/14651858.CD012067.pub2
Lyttle 2015
Lyttle MD, O’Sullivan R, Doull I, Hartshorn S, Morris
I, Powell CV. Variation in treatment of acute childhood
wheeze in emergency departments of the United Kingdom
and Ireland: an international survey of clinician practice.
Archives of Disease in Childhood 2015;100(2):121–5.
Martinez 1995
Martinez FD, Wright AL, Taussig LM, Holberg CJ,
Halonen M, Morgan WJ. Asthma and wheezing in the first
six years of life. The Group Health Medical Associates. New
England Journal of Medicine 1995;332(3):133–8.
Morris 2015
Morris I, Lyttle MD, O’Sullivan R, Sargant N, Doull IJ,
Powell CV. Which intravenous bronchodilators are being
administered to children presenting with acute severe
wheeze in the UK and Ireland?. Thorax 2015;70(1):88–91.
Naspitz 1987
Naspitz CK, Sole D, Wandalsen N. Treatment of acute
attacks of bronchial asthma. A comparative study of
epinephrine (subcutaneous) and fenoterol (inhalation).
Annals of Allergy 1987;59(1):21–4.
Nath 2015
Nath JB, Hsia RY. Children’s emergency department use
for asthma, 2001-2010. Academic Pediatrics 2015;15(2):
225–30.
National Asthma Council Australia 2016
National Asthma Council Australia. Australian Asthma
Handbook, Version 1.2. National Asthma Council
Australia, Melbourne, 2016. www.asthmahandbook.org.au/
download-order/complete-handbook (accessed 3 August
2017).
Neame 2015
Neame M, Aragon O, Fernandes RM, Sinha I. Salbutamol
or aminophylline for acute severe asthma: how to choose
which one, when and why?. Archives of Disease in Childhood.
Education and Practice Edition 2015;100(4):215–22.
NHLBI 2007
National Heart, Lung, and Blood Institute (NHLBI).
National asthma education and prevention program expert
panel report 3: guidelines for the diagnosis and management
of asthma 2007. www.nhlbi.nih.gov/health-pro/guidelines/
current/asthma-guidelines/full-report (accessed 3 August
2017).
O’Connor 2014
O’Connor MG, Saville BR, Hartert TV, Arnold DH.
Treatment variability of asthma exacerbations in a pediatric
emergency department using a severity-based management
protocol. Clinical Pediatrics 2014;53(13):1288–90.
Papadopoulos 2012
Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A,
Gern J, Lemanske R, et al. International consensus on
(ICON) pediatric asthma. Allergy 2012;67(8):976–97.
Parkin 1996
Parkin PC, Macarthur C, Saunders NR, Diamond SA,
Winders PM. Development of a clinical asthma score for
use in hospitalized children between 1 and 5 years of age.
Journal of Clinical Epidemiology 1996;49(8):821–5.
9Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Powell 2003
Powell CV, Kelly AM, Kerr D. Lack of agreement in
classification of the severity of acute asthma between
emergency physician assessment and classification using
the National Asthma Council Australia guidelines (1998).
Emergency Medicine (Fremantle, W.A.) 2003;15(1):49–53.
Powell 2012
Powell C, Dwan K, Milan SJ, Beasley R, Hughes R,
Knopp-Sihota JA, et al. Inhaled magnesium sulfate
in the treatment of acute asthma. Cochrane Database
of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/
14651858.CD003898.pub5
Rees 1967
Rees HA, Millar JS, Donald KW. Adrenaline in bronchial
asthma. Lancet 1967;2(7527):1164–7.
Rehder 2017
Rehder KJ. Adjunct therapies for refractory status
asthmaticus in children. Respiratory Care 2017;62(6):
849–65.
Schüneman 2017
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT,
Deeks JJ, Glasziou P, et al. on behalf of the Cochrane
Applicability and Recommendations Methods Group.
Chapter 12: Interpreting results and drawing conclusions.
In: Higgins JPT, Churchill R, Chandler J, Cumpston MS
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.2.0 (updated June 2017).
The Cochrane Collaboration, 2017. Available from
www.training.cochrane.org/handbook.
Shim 1984
Shim C. Adrenergic agonists and bronchodilator aerosol
therapy in asthma. Clinics in Chest Medicine 1984;5(4):
659–68.
Travers 2012
Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe
BH. Addition of intravenous beta2-agonists to inhaled
beta2-agonists for acute asthma. Cochrane Database of
Systematic Reviews 2012, Issue 12. [DOI: 10.1002/
14651858.CD010179
Vezina 2014
Vezina K, Chauhan BF, Ducharme FM. Inhaled
anticholinergics and short-acting beta2-agonists versus
short-acting beta2-agonists alone for children with acute
asthma in hospital. Cochrane Database of Systematic Reviews
2014, Issue 7. [DOI: 10.1002/14651858.CD010283.pub2
Weiss 2011
Weiss AJ, Wier LM, Stocks C, Blanchard J. Overview
of emergency department visits in the United States,
2011. HCUP Statistical Brief #174. June 2014.
Agency for Healthcare Research and Quality, Rockville,
MD.. www.hcup-us.ahrq.gov/reports/statbriefs/sb174-
Emergency-Department-Visits-Overview.pdf (accessed 2
November 2017).
Whiting 2016
Whiting P, Savovic J, Higgins JP, Caldwell DM, Reeves
BC, Shea B, et al. ROBIS: a new tool to assess risk of bias
in systematic reviews was developed. Journal of Clinical
Epidemiology 2016;69:225–34.
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. Search strategy for Cochrane Database of Systematic Reviews
#1 MeSH descriptor: [Asthma] explode all trees
#2 MeSH descriptor: [Respiratory Sounds] this term only
#3 asthma*:ti,ab,kw
#4 #1 or #2 or #3
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Appendix 2. Data collection tool
Details of the review
• First author name
• Year of publication
• Number of included primary studies
• Countries and years pf the original studies
• Eligibility criteria of included studies
• Numbers of included participants
• Sample size of included RCTs
• Details of included RCTs
Participant characteristics
• Age
• Severity of asthma
• Definition of exacerbation of asthma for each RCT
• Treatment before enrolment
Setting
• Emergency department
• Hospital ward
• Intensive care unit
Types of interventions
• Name of medication/intervention
• Dose of medication/intervention
• Duration of treatment
• Frequency of intervention administration
Description of the comparative treatment (placebo, regular doses of bronchodilators)
Description of outcome measures used
For each outcome measure
• Number of participants in the intervention group
• Number of participants in the control group
• Intervention event rate
• Control event rate
• Effect estimates for pooled results (risk ratio, odds ratio, hazard ratio, standardised mean difference, or absolute risk reduction
and corresponding 95% confidence intervals)
• Details of statistical tests for heterogeneity
◦ Chi2 test
◦ I2 test
Predefined primary outcome measures
• Length of stay
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◦ Emergency department length of stay
◦ Hospital length of stay
• Emergency department disposition
◦ Hospital admission
◦ ICU admission
◦ ED discharge
• Adverse events
◦ Vomiting
◦ Nausea
◦ Tremor
◦ Tachycardia
◦ Arrhythmia
◦ Convulsion
◦ Other (specify)
Predefined secondary outcome measures
• Symptom scores/clinical asthma scores
◦ Name of score
◦ Definition/reference
◦ Time of recording of outcome measure
◦ Interpretation of score result (cutoff )
• Lung function tests
◦ Examples: peak expiratory flow rate, forced expiratory volume in one second, and other measures
◦ Name of test
◦ Definition/reference
◦ Time of recording of outcome measure
◦ Interpretation of test result (cutoff )
• Vital signs
◦ Examples: pulse, blood pressure, respiratory rate, pulse oximetry
◦ Name of vital sign
◦ Definition/reference
◦ Time of recording of vital signs
◦ Interpretation of vital signs results (cutoff )
• Requirement for additional bronchodilator treatment
◦ Name of outcome measure
◦ Definition/reference
◦ Time of recording of outcome
◦ Interpretation
• Requirement for respiratory support
◦ Intubation
◦ Time of recording of outcome
• Non-invasive ventilation
◦ Name of outcome measure (CPAP, BiPap, etc.)
◦ Definition/reference
◦ Time of recording of outcome
◦ Interpretation
• Economic outcomes/healthcare costs
◦ Definition/reference
◦ Time of recording of outcome
◦ Interpretation
• Additional outcome measures
◦ Name of outcome measure
◦ Definition/reference
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◦ Time of recording of outcome
◦ Interpretation
Risk of bias assessments of RCTs included in the reviews.
Quality assessment tools used (e.g. GRADE) along with the mean or median and range of any reported quality scores.
Conclusions of each review.
Review recommendations for further research.
If the included systematic review includes all studies relevant to a particular outcome, we will extract summary data alone. If data are
required to be extracted from a subgroup of studies (i.e. only children), then we will extract study-level data from all RCTs included in
the review. These data will include numerical primary study results and risk of bias data.
Appendix 3. ROBIS tool
The ROBIS tool to assess risk of bias in systematic reviews consists of the following assessment criteria.
Phase 1. Assessing relevance (optional)
For intervention reviews, assessment of patients/populations; interventions; comparators; and outcomes.
Phase 2. Identifying concerns with the review process
Domain 1. Study eligibility criteria.
• Did the review adhere to predefined objectives and eligibility criteria?
• Were the eligibility criteria appropriate for the review question?
• Were eligibility criteria unambiguous?
• Were all restrictions in eligibility criteria based on study characteristics appropriate?
• Were any restrictions in eligibility criteria based on sources of information appropriate?
Domain 2. Identification and selection of studies
• Did the search include an appropriate range of databases/electronic sources for published and unpublished reports?
• Were methods additional to database searching used to identify relevant reports?
• Were the terms and structure of the search strategy likely to retrieve as many eligible studies as possible?
• Were restrictions based on date, publication format, or language appropriate?
• Were efforts made to minimise error in selection of studies?
Domain 3. Data collection and study appraisal
• Were efforts made to minimise errors in data collection?
• Were sufficient study characteristics available for both review authors and readers to be able to interpret the results?
• Were all relevant study results collected for use in the synthesis?
• Was risk of bias (or methodological quality) formally assessed by appropriate criteria?
• Were efforts made to minimise error in risk of bias assessment?
Domain 4. Synthesis and findings
• Did the synthesis include all studies that it should?
• Were all predefined analyses reported or departures explained?
• Was the synthesis appropriate given the nature and similarity of research questions, study designs, and outcomes across included
studies?
• Was between-study variation (heterogeneity) minimal or addressed in the synthesis?
• Were the findings robust (e.g. as demonstrated through funnel plot or sensitivity analyses)?
• Were biases in primary studies minimal or addressed in the synthesis?
We will rate each criterion as Y = Yes, PY = Probably yes, PN = Probably no, N = No, NI = No information.
We will then interpret each domain as having ’Low’, ’High’, or ’Unclear’ concerns for bias.
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Phase 3. Judging the risk of bias
Concerns from each domain are summarised.
We will then determine whether the conclusions are supported by the evidence presented.
• Did interpretation of the findings address all concerns identified in domains one through four?
• Was the relevance of identified studies to the review’s research question appropriately considered?
• Did the review authors avoid emphasising results on the basis of their statistical significance?
• Risk of bias in the review? LOW/HIGH/UNCLEAR.
C O N T R I B U T I O N S O F A U T H O R S
SC - drafting of background and protocol methods.
SRD - drafting of background and protocol methods.
CP - drafting of background and protocol methods.
AG - drafting of background and protocol methods.
FEB - drafting of background and protocol methods.
CL - drafting of protocol methods, critical review of background.
D E C L A R A T I O N S O F I N T E R E S T
SC: none known.
SRD: none known.
CP: none known.
AG: none known.
FEB: none known.
CL: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Cardiff University, UK.
CP’s time is paid for in part by Cardiff University.
• Monash University, Australia.
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SRD’s salary is paid by Auckland District Health Board.
• Royal Children’s Hospital Foundation, Melbourne, Australia.
FEB’s time was funded in part by a grant from the Royal Children’s Hospital Foundation, Melbourne, Australia.
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Research Institute, Melbourne, Australia.
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